Investments, Funding & Disinvestment

The deal combines acquisition with a concurrent private placement of up to US$64 million in gross proceeds before expenses, strengthening development funding.

Scientia Vascular develops advanced access products designed to improve simplicity and precision during neurovascular interventions.

The partnership grants Lilly global rights to AlzeCure’s preclinical small-molecule candidate, ACD680, which targets the biology of Alzheimer’s disease.

Novanta plans to finance the acquisition using a combination of cash on hand, proceeds from a recently completed US$300 million equity raise, and its existing credit facilities.

The Hatfield facility, located north of London, will undergo a phased upgrade that will significantly expand its manufacturing, packaging and distribution capabilities.

The project includes a specialised training academy designed to develop advanced skills in biotechnology, quality control, and vaccine production, ensuring a steady pipeline of qualified personnel to support long-term operations and sector growth.

The agreement includes an upfront payment of US$1.25 billion, with additional milestone-based payments of up to US$750 million tied to future sales performance.

The company has invested nearly US$5 billion in the United States over the past 15 years, expanding its manufacturing, research, development, and distribution infrastructure.

The deal integrates Firefly Bio’s experimental Firelink degrader-antibody conjugate platform into J&J’s oncology research and development portfolio, marking a significant step in its long-term strategy to enhance targeted drug delivery systems.

The move comes as Teva advances plans to divest its API unit, Teva Active Pharmaceutical Ingredients (TAPI), a process first announced in January 2024.